Report cover image

Human Genetics Market By Test (NIPT, Carrier Testing, Pharmacogenomic Testing, Karyotype Testing, Thrombophilia Testing, Septin 9 Biomarker Testing, NGS, Others) , By Application (Wellness & E-Commerce, Preventive Medicine, Diagnostic & Treatment) : Globa

Publisher Allied Market Research
Published Sep 01, 2024
Length 320 Pages
SKU # ALMR19510453

Description

Human Genetics Market By Test (NIPT, Carrier Testing, Pharmacogenomic Testing, Karyotype Testing, Thrombophilia Testing, Septin 9 Biomarker Testing, NGS, Others) , By Application (Wellness & E-Commerce, Preventive Medicine, Diagnostic & Treatment) : Global Opportunity Analysis and Industry Forecast, 2024-2033


Human Genetics Market Expected to Garner $71.1 Billion by 2033, Growing at a CAGR of 10.8%

The global human genetics market is expected to grow primarily due to the growing prevalence of genetic disorders and rising application of genetics in oncology, rare diseases, & infectious diseases. The North America region is predicted to witness profitable growth by 2033.

As per the report published by Research Dive, the global human genetics market was valued at $27.0 billion in 2023 and is expected to register a revenue of $71.1 billion by 2033 at a CAGR of 10.8% during the forecast period 2024-2033.

Dynamics of the Market

The rising prevalence of genetic disorders in newborns, growth in direct-to-consumer genetic testing and personalized genomics, and increasing application of genetics in oncology, rare diseases, & infectious diseases are expected to make the human genetics market a highly profitable one during the forecast period.

However, according to market analysts, concerns about genetic data privacy and potential misuse of genetic information might restrain the growth of the market.

Advances in patterned flow cell technology and expansion of biotechnology & pharmaceutical collaborations in genetic research present significant opportunities for human genetics market growth. Moreover, the development and application of cutting-edge technologies, such as patterned flow cell technology, offer opportunities for more efficient and accurate genetic analysis.

Key Players of the Market

The major players of the human genetics market include Myriad Genetics, Eurofins Megalab S.A, Synlab Group, Biomarker Technology, Elabscience Biotechnology Inc, Echevarne Laboratory, NIMGenetics, FullGenomics, Sistemas Genómicos, Atrys Health, and GENinCode.

What the Report Covers

In addition to the details highlighted in this description, the comprehensive final report delves into essential market aspects. These encompass a market overview, SWOT analysis, market dynamics, Porter’s five forces analysis, segmentation (key trends, regional analysis, and forecast analysis), and company profiles (including company overview, product portfolio, operating segments, strategic initiatives, and financial performance).

Key Market Segments

By Test

NIPT
Carrier Testing
Pharmacogenomic Testing
Karyotype Testing
Thrombophilia Testing
Septin 9 Biomarker Testing
NGS
Others

By Application

Wellness E-Commerce
Preventive Medicine
Diagnostic Treatment

By Region

North America
U.S.
Canada
Mexico
Europe
France
Germany
Italy
Spain
UK
Rest of Europe
Asia-Pacific
China
Japan
India
South Korea
Australia
Rest of Asia-Pacific
LAMEA
Brazil
South Africa
Saudi Arabia
UAE
Rest of LAMEA

Key Market Players

Myriad Genetics
Synlab Group
Eurofins Megalab S.A.
Biomarker Technologies
Echevarne Laboratory
Elabscience Biotechnology Inc
nimgenetics
Sistemas Genómicos
FullGenomics
GENinCode
atrys health

Table of Contents

320 Pages
CHAPTER 1: INTRODUCTION
1.1. Report Description
1.2. Key Market Segments
1.3. Key Benefits
1.4. Research Methodology
1.4.1. Primary Research
1.4.2. Secondary Research
1.4.3. Analyst Tools and Models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. CXO Perspective
CHAPTER 3: MARKET LANDSCAPE
3.1. Market Definition and Scope
3.2. Key Findings
3.2.1. Top Investment Pockets
3.2.2. Top Winning Strategies
3.3. Porter's Five Forces Analysis
3.3.1. Bargaining Power of Suppliers
3.3.2. Threat of New Entrants
3.3.3. Threat of Substitutes
3.3.4. Competitive Rivalry
3.3.5. Bargaining Power among Buyers
3.4. Market Dynamics
3.4.1. Drivers
3.4.2. Restraints
3.4.3. Opportunities
CHAPTER 4: HUMAN GENETICS MARKET, BY TEST
4.1. Market Overview
4.1.1 Market Size and Forecast, By Test
4.2. NIPT
4.2.1. Key Market Trends, Growth Factors and Opportunities
4.2.2. Market Size and Forecast, By Region
4.2.3. Market Share Analysis, By Country
4.3. Carrier Testing
4.3.1. Key Market Trends, Growth Factors and Opportunities
4.3.2. Market Size and Forecast, By Region
4.3.3. Market Share Analysis, By Country
4.4. Pharmacogenomic Testing
4.4.1. Key Market Trends, Growth Factors and Opportunities
4.4.2. Market Size and Forecast, By Region
4.4.3. Market Share Analysis, By Country
4.5. Karyotype Testing
4.5.1. Key Market Trends, Growth Factors and Opportunities
4.5.2. Market Size and Forecast, By Region
4.5.3. Market Share Analysis, By Country
4.6. Thrombophilia Testing
4.6.1. Key Market Trends, Growth Factors and Opportunities
4.6.2. Market Size and Forecast, By Region
4.6.3. Market Share Analysis, By Country
4.7. Septin 9 Biomarker Testing
4.7.1. Key Market Trends, Growth Factors and Opportunities
4.7.2. Market Size and Forecast, By Region
4.7.3. Market Share Analysis, By Country
4.8. NGS
4.8.1. Key Market Trends, Growth Factors and Opportunities
4.8.2. Market Size and Forecast, By Region
4.8.3. Market Share Analysis, By Country
4.9. Others
4.9.1. Key Market Trends, Growth Factors and Opportunities
4.9.2. Market Size and Forecast, By Region
4.9.3. Market Share Analysis, By Country
CHAPTER 5: HUMAN GENETICS MARKET, BY APPLICATION
5.1. Market Overview
5.1.1 Market Size and Forecast, By Application
5.2. Wellness E-Commerce
5.2.1. Key Market Trends, Growth Factors and Opportunities
5.2.2. Market Size and Forecast, By Region
5.2.3. Market Share Analysis, By Country
5.3. Preventive Medicine
5.3.1. Key Market Trends, Growth Factors and Opportunities
5.3.2. Market Size and Forecast, By Region
5.3.3. Market Share Analysis, By Country
5.4. Diagnostic Treatment
5.4.1. Key Market Trends, Growth Factors and Opportunities
5.4.2. Market Size and Forecast, By Region
5.4.3. Market Share Analysis, By Country
CHAPTER 6: HUMAN GENETICS MARKET, BY REGION
6.1. Market Overview
6.1.1 Market Size and Forecast, By Region
6.2. North America
6.2.1. Key Market Trends and Opportunities
6.2.2. Market Size and Forecast, By Test
6.2.3. Market Size and Forecast, By Application
6.2.4. Market Size and Forecast, By Country
6.2.5. U.S. Human Genetics Market
6.2.5.1. Market Size and Forecast, By Test
6.2.5.2. Market Size and Forecast, By Application
6.2.6. Canada Human Genetics Market
6.2.6.1. Market Size and Forecast, By Test
6.2.6.2. Market Size and Forecast, By Application
6.2.7. Mexico Human Genetics Market
6.2.7.1. Market Size and Forecast, By Test
6.2.7.2. Market Size and Forecast, By Application
6.3. Europe
6.3.1. Key Market Trends and Opportunities
6.3.2. Market Size and Forecast, By Test
6.3.3. Market Size and Forecast, By Application
6.3.4. Market Size and Forecast, By Country
6.3.5. France Human Genetics Market
6.3.5.1. Market Size and Forecast, By Test
6.3.5.2. Market Size and Forecast, By Application
6.3.6. Germany Human Genetics Market
6.3.6.1. Market Size and Forecast, By Test
6.3.6.2. Market Size and Forecast, By Application
6.3.7. Italy Human Genetics Market
6.3.7.1. Market Size and Forecast, By Test
6.3.7.2. Market Size and Forecast, By Application
6.3.8. Spain Human Genetics Market
6.3.8.1. Market Size and Forecast, By Test
6.3.8.2. Market Size and Forecast, By Application
6.3.9. UK Human Genetics Market
6.3.9.1. Market Size and Forecast, By Test
6.3.9.2. Market Size and Forecast, By Application
6.3.10. Rest Of Europe Human Genetics Market
6.3.10.1. Market Size and Forecast, By Test
6.3.10.2. Market Size and Forecast, By Application
6.4. Asia-Pacific
6.4.1. Key Market Trends and Opportunities
6.4.2. Market Size and Forecast, By Test
6.4.3. Market Size and Forecast, By Application
6.4.4. Market Size and Forecast, By Country
6.4.5. China Human Genetics Market
6.4.5.1. Market Size and Forecast, By Test
6.4.5.2. Market Size and Forecast, By Application
6.4.6. Japan Human Genetics Market
6.4.6.1. Market Size and Forecast, By Test
6.4.6.2. Market Size and Forecast, By Application
6.4.7. India Human Genetics Market
6.4.7.1. Market Size and Forecast, By Test
6.4.7.2. Market Size and Forecast, By Application
6.4.8. South Korea Human Genetics Market
6.4.8.1. Market Size and Forecast, By Test
6.4.8.2. Market Size and Forecast, By Application
6.4.9. Australia Human Genetics Market
6.4.9.1. Market Size and Forecast, By Test
6.4.9.2. Market Size and Forecast, By Application
6.4.10. Rest of Asia-Pacific Human Genetics Market
6.4.10.1. Market Size and Forecast, By Test
6.4.10.2. Market Size and Forecast, By Application
6.5. LAMEA
6.5.1. Key Market Trends and Opportunities
6.5.2. Market Size and Forecast, By Test
6.5.3. Market Size and Forecast, By Application
6.5.4. Market Size and Forecast, By Country
6.5.5. Brazil Human Genetics Market
6.5.5.1. Market Size and Forecast, By Test
6.5.5.2. Market Size and Forecast, By Application
6.5.6. South Africa Human Genetics Market
6.5.6.1. Market Size and Forecast, By Test
6.5.6.2. Market Size and Forecast, By Application
6.5.7. Saudi Arabia Human Genetics Market
6.5.7.1. Market Size and Forecast, By Test
6.5.7.2. Market Size and Forecast, By Application
6.5.8. UAE Human Genetics Market
6.5.8.1. Market Size and Forecast, By Test
6.5.8.2. Market Size and Forecast, By Application
6.5.9. Rest of LAMEA Human Genetics Market
6.5.9.1. Market Size and Forecast, By Test
6.5.9.2. Market Size and Forecast, By Application
CHAPTER 7: COMPETITIVE LANDSCAPE
7.1. Introduction
7.2. Top Winning Strategies
7.3. Product Mapping Of Top 10 Player
7.4. Competitive Dashboard
7.5. Competitive Heatmap
7.6. Top Player Positioning, 2023
CHAPTER 8: COMPANY PROFILES
8.1. Myriad Genetics
8.1.1. Company Overview
8.1.2. Key Executives
8.1.3. Company Snapshot
8.1.4. Operating Business Segments
8.1.5. Product Portfolio
8.1.6. Business Performance
8.1.7. Key Strategic Moves and Developments
8.2. Synlab Group
8.2.1. Company Overview
8.2.2. Key Executives
8.2.3. Company Snapshot
8.2.4. Operating Business Segments
8.2.5. Product Portfolio
8.2.6. Business Performance
8.2.7. Key Strategic Moves and Developments
8.3. Eurofins Megalab S.A.
8.3.1. Company Overview
8.3.2. Key Executives
8.3.3. Company Snapshot
8.3.4. Operating Business Segments
8.3.5. Product Portfolio
8.3.6. Business Performance
8.3.7. Key Strategic Moves and Developments
8.4. Biomarker Technologies
8.4.1. Company Overview
8.4.2. Key Executives
8.4.3. Company Snapshot
8.4.4. Operating Business Segments
8.4.5. Product Portfolio
8.4.6. Business Performance
8.4.7. Key Strategic Moves and Developments
8.5. Echevarne Laboratory
8.5.1. Company Overview
8.5.2. Key Executives
8.5.3. Company Snapshot
8.5.4. Operating Business Segments
8.5.5. Product Portfolio
8.5.6. Business Performance
8.5.7. Key Strategic Moves and Developments
8.6. Elabscience Biotechnology Inc
8.6.1. Company Overview
8.6.2. Key Executives
8.6.3. Company Snapshot
8.6.4. Operating Business Segments
8.6.5. Product Portfolio
8.6.6. Business Performance
8.6.7. Key Strategic Moves and Developments
8.7. Nimgenetics
8.7.1. Company Overview
8.7.2. Key Executives
8.7.3. Company Snapshot
8.7.4. Operating Business Segments
8.7.5. Product Portfolio
8.7.6. Business Performance
8.7.7. Key Strategic Moves and Developments
8.8. Sistemas Genómicos
8.8.1. Company Overview
8.8.2. Key Executives
8.8.3. Company Snapshot
8.8.4. Operating Business Segments
8.8.5. Product Portfolio
8.8.6. Business Performance
8.8.7. Key Strategic Moves and Developments
8.9. FullGenomics
8.9.1. Company Overview
8.9.2. Key Executives
8.9.3. Company Snapshot
8.9.4. Operating Business Segments
8.9.5. Product Portfolio
8.9.6. Business Performance
8.9.7. Key Strategic Moves and Developments
8.10. GENinCode
8.10.1. Company Overview
8.10.2. Key Executives
8.10.3. Company Snapshot
8.10.4. Operating Business Segments
8.10.5. Product Portfolio
8.10.6. Business Performance
8.10.7. Key Strategic Moves and Developments
8.11. Atrys Health
8.11.1. Company Overview
8.11.2. Key Executives
8.11.3. Company Snapshot
8.11.4. Operating Business Segments
8.11.5. Product Portfolio
8.11.6. Business Performance
8.11.7. Key Strategic Moves and Developments
LIST OF TABLES
TABLE 1. GLOBAL HUMAN GENETICS MARKET, BY TEST, 2024 - 2033 ($MILLION)
TABLE 2. HUMAN GENETICS MARKET FOR NIPT, BY REGION, 2024 - 2033 ($MILLION)
TABLE 3. HUMAN GENETICS MARKET FOR CARRIER TESTING, BY REGION, 2024 - 2033 ($MILLION)
TABLE 4. HUMAN GENETICS MARKET FOR PHARMACOGENOMIC TESTING, BY REGION, 2024 - 2033 ($MILLION)
TABLE 5. HUMAN GENETICS MARKET FOR KARYOTYPE TESTING, BY REGION, 2024 - 2033 ($MILLION)
TABLE 6. HUMAN GENETICS MARKET FOR THROMBOPHILIA TESTING, BY REGION, 2024 - 2033 ($MILLION)
TABLE 7. HUMAN GENETICS MARKET FOR SEPTIN 9 BIOMARKER TESTING, BY REGION, 2024 - 2033 ($MILLION)
TABLE 8. HUMAN GENETICS MARKET FOR NGS, BY REGION, 2024 - 2033 ($MILLION)
TABLE 9. HUMAN GENETICS MARKET FOR OTHERS, BY REGION, 2024 - 2033 ($MILLION)
TABLE 10. GLOBAL HUMAN GENETICS MARKET, BY APPLICATION, 2024 - 2033 ($MILLION)
TABLE 11. HUMAN GENETICS MARKET FOR WELLNESS E-COMMERCE, BY REGION, 2024 - 2033 ($MILLION)
TABLE 12. HUMAN GENETICS MARKET FOR PREVENTIVE MEDICINE, BY REGION, 2024 - 2033 ($MILLION)
TABLE 13. HUMAN GENETICS MARKET FOR DIAGNOSTIC TREATMENT, BY REGION, 2024 - 2033 ($MILLION)
TABLE 14. HUMAN GENETICS MARKET, BY REGION, 2024 - 2033 ($MILLION)
TABLE 15. NORTH AMERICA HUMAN GENETICS MARKET, BY COUNTRY, 2024 - 2033 ($MILLION)
TABLE 16. NORTH AMERICA HUMAN GENETICS MARKET, BY TEST, 2024 - 2033 ($MILLION)
TABLE 17. NORTH AMERICA HUMAN GENETICS MARKET, BY APPLICATION, 2024 - 2033 ($MILLION)
TABLE 18. U.S. HUMAN GENETICS MARKET, BY TEST, 2024 - 2033 ($MILLION)
TABLE 19. U.S. HUMAN GENETICS MARKET, BY APPLICATION, 2024 - 2033 ($MILLION)
TABLE 20. CANADA HUMAN GENETICS MARKET, BY TEST, 2024 - 2033 ($MILLION)
TABLE 21. CANADA HUMAN GENETICS MARKET, BY APPLICATION, 2024 - 2033 ($MILLION)
TABLE 22. MEXICO HUMAN GENETICS MARKET, BY TEST, 2024 - 2033 ($MILLION)
TABLE 23. MEXICO HUMAN GENETICS MARKET, BY APPLICATION, 2024 - 2033 ($MILLION)
TABLE 24. EUROPE HUMAN GENETICS MARKET, BY COUNTRY, 2024 - 2033 ($MILLION)
TABLE 25. EUROPE HUMAN GENETICS MARKET, BY TEST, 2024 - 2033 ($MILLION)
TABLE 26. EUROPE HUMAN GENETICS MARKET, BY APPLICATION, 2024 - 2033 ($MILLION)
TABLE 27. FRANCE HUMAN GENETICS MARKET, BY TEST, 2024 - 2033 ($MILLION)
TABLE 28. FRANCE HUMAN GENETICS MARKET, BY APPLICATION, 2024 - 2033 ($MILLION)
TABLE 29. GERMANY HUMAN GENETICS MARKET, BY TEST, 2024 - 2033 ($MILLION)
TABLE 30. GERMANY HUMAN GENETICS MARKET, BY APPLICATION, 2024 - 2033 ($MILLION)
TABLE 31. ITALY HUMAN GENETICS MARKET, BY TEST, 2024 - 2033 ($MILLION)
TABLE 32. ITALY HUMAN GENETICS MARKET, BY APPLICATION, 2024 - 2033 ($MILLION)
TABLE 33. SPAIN HUMAN GENETICS MARKET, BY TEST, 2024 - 2033 ($MILLION)
TABLE 34. SPAIN HUMAN GENETICS MARKET, BY APPLICATION, 2024 - 2033 ($MILLION)
TABLE 35. UK HUMAN GENETICS MARKET, BY TEST, 2024 - 2033 ($MILLION)
TABLE 36. UK HUMAN GENETICS MARKET, BY APPLICATION, 2024 - 2033 ($MILLION)
TABLE 37. REST OF EUROPE HUMAN GENETICS MARKET, BY TEST, 2024 - 2033 ($MILLION)
TABLE 38. REST OF EUROPE HUMAN GENETICS MARKET, BY APPLICATION, 2024 - 2033 ($MILLION)
TABLE 39. ASIA-PACIFIC HUMAN GENETICS MARKET, BY COUNTRY, 2024 - 2033 ($MILLION)
TABLE 40. ASIA-PACIFIC HUMAN GENETICS MARKET, BY TEST, 2024 - 2033 ($MILLION)
TABLE 41. ASIA-PACIFIC HUMAN GENETICS MARKET, BY APPLICATION, 2024 - 2033 ($MILLION)
TABLE 42. CHINA HUMAN GENETICS MARKET, BY TEST, 2024 - 2033 ($MILLION)
TABLE 43. CHINA HUMAN GENETICS MARKET, BY APPLICATION, 2024 - 2033 ($MILLION)
TABLE 44. JAPAN HUMAN GENETICS MARKET, BY TEST, 2024 - 2033 ($MILLION)
TABLE 45. JAPAN HUMAN GENETICS MARKET, BY APPLICATION, 2024 - 2033 ($MILLION)
TABLE 46. INDIA HUMAN GENETICS MARKET, BY TEST, 2024 - 2033 ($MILLION)
TABLE 47. INDIA HUMAN GENETICS MARKET, BY APPLICATION, 2024 - 2033 ($MILLION)
TABLE 48. SOUTH KOREA HUMAN GENETICS MARKET, BY TEST, 2024 - 2033 ($MILLION)
TABLE 49. SOUTH KOREA HUMAN GENETICS MARKET, BY APPLICATION, 2024 - 2033 ($MILLION)
TABLE 50. AUSTRALIA HUMAN GENETICS MARKET, BY TEST, 2024 - 2033 ($MILLION)
TABLE 51. AUSTRALIA HUMAN GENETICS MARKET, BY APPLICATION, 2024 - 2033 ($MILLION)
TABLE 52. REST OF ASIA-PACIFIC HUMAN GENETICS MARKET, BY TEST, 2024 - 2033 ($MILLION)
TABLE 53. REST OF ASIA-PACIFIC HUMAN GENETICS MARKET, BY APPLICATION, 2024 - 2033 ($MILLION)
TABLE 54. LAMEA HUMAN GENETICS MARKET, BY COUNTRY, 2024 - 2033 ($MILLION)
TABLE 55. LAMEA HUMAN GENETICS MARKET, BY TEST, 2024 - 2033 ($MILLION)
TABLE 56. LAMEA HUMAN GENETICS MARKET, BY APPLICATION, 2024 - 2033 ($MILLION)
TABLE 57. BRAZIL HUMAN GENETICS MARKET, BY TEST, 2024 - 2033 ($MILLION)
TABLE 58. BRAZIL HUMAN GENETICS MARKET, BY APPLICATION, 2024 - 2033 ($MILLION)
TABLE 59. SOUTH AFRICA HUMAN GENETICS MARKET, BY TEST, 2024 - 2033 ($MILLION)
TABLE 60. SOUTH AFRICA HUMAN GENETICS MARKET, BY APPLICATION, 2024 - 2033 ($MILLION)
TABLE 61. SAUDI ARABIA HUMAN GENETICS MARKET, BY TEST, 2024 - 2033 ($MILLION)
TABLE 62. SAUDI ARABIA HUMAN GENETICS MARKET, BY APPLICATION, 2024 - 2033 ($MILLION)
TABLE 63. UAE HUMAN GENETICS MARKET, BY TEST, 2024 - 2033 ($MILLION)
TABLE 64. UAE HUMAN GENETICS MARKET, BY APPLICATION, 2024 - 2033 ($MILLION)
TABLE 65. REST OF LAMEA HUMAN GENETICS MARKET, BY TEST, 2024 - 2033 ($MILLION)
TABLE 66. REST OF LAMEA HUMAN GENETICS MARKET, BY APPLICATION, 2024 - 2033 ($MILLION)
TABLE 67. MYRIAD GENETICS: KEY EXECUTIVES
TABLE 68. MYRIAD GENETICS: COMPANY SNAPSHOT
TABLE 69. MYRIAD GENETICS: OPERATING SEGMENTS
TABLE 70. MYRIAD GENETICS: PRODUCT PORTFOLIO
TABLE 71. MYRIAD GENETICS: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 72. SYNLAB GROUP: KEY EXECUTIVES
TABLE 73. SYNLAB GROUP: COMPANY SNAPSHOT
TABLE 74. SYNLAB GROUP: OPERATING SEGMENTS
TABLE 75. SYNLAB GROUP: PRODUCT PORTFOLIO
TABLE 76. SYNLAB GROUP: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 77. EUROFINS MEGALAB S.A.: KEY EXECUTIVES
TABLE 78. EUROFINS MEGALAB S.A.: COMPANY SNAPSHOT
TABLE 79. EUROFINS MEGALAB S.A.: OPERATING SEGMENTS
TABLE 80. EUROFINS MEGALAB S.A.: PRODUCT PORTFOLIO
TABLE 81. EUROFINS MEGALAB S.A.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 82. BIOMARKER TECHNOLOGIES: KEY EXECUTIVES
TABLE 83. BIOMARKER TECHNOLOGIES: COMPANY SNAPSHOT
TABLE 84. BIOMARKER TECHNOLOGIES: OPERATING SEGMENTS
TABLE 85. BIOMARKER TECHNOLOGIES: PRODUCT PORTFOLIO
TABLE 86. BIOMARKER TECHNOLOGIES: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 87. ECHEVARNE LABORATORY: KEY EXECUTIVES
TABLE 88. ECHEVARNE LABORATORY: COMPANY SNAPSHOT
TABLE 89. ECHEVARNE LABORATORY: OPERATING SEGMENTS
TABLE 90. ECHEVARNE LABORATORY: PRODUCT PORTFOLIO
TABLE 91. ECHEVARNE LABORATORY: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 92. ELABSCIENCE BIOTECHNOLOGY INC: KEY EXECUTIVES
TABLE 93. ELABSCIENCE BIOTECHNOLOGY INC: COMPANY SNAPSHOT
TABLE 94. ELABSCIENCE BIOTECHNOLOGY INC: OPERATING SEGMENTS
TABLE 95. ELABSCIENCE BIOTECHNOLOGY INC: PRODUCT PORTFOLIO
TABLE 96. ELABSCIENCE BIOTECHNOLOGY INC: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 97. NIMGENETICS: KEY EXECUTIVES
TABLE 98. NIMGENETICS: COMPANY SNAPSHOT
TABLE 99. NIMGENETICS: OPERATING SEGMENTS
TABLE 100. NIMGENETICS: PRODUCT PORTFOLIO
TABLE 101. NIMGENETICS: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 102. SISTEMAS GENóMICOS: KEY EXECUTIVES
TABLE 103. SISTEMAS GENóMICOS: COMPANY SNAPSHOT
TABLE 104. SISTEMAS GENóMICOS: OPERATING SEGMENTS
TABLE 105. SISTEMAS GENóMICOS: PRODUCT PORTFOLIO
TABLE 106. SISTEMAS GENóMICOS: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 107. FULLGENOMICS: KEY EXECUTIVES
TABLE 108. FULLGENOMICS: COMPANY SNAPSHOT
TABLE 109. FULLGENOMICS: OPERATING SEGMENTS
TABLE 110. FULLGENOMICS: PRODUCT PORTFOLIO
TABLE 111. FULLGENOMICS: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 112. GENINCODE: KEY EXECUTIVES
TABLE 113. GENINCODE: COMPANY SNAPSHOT
TABLE 114. GENINCODE: OPERATING SEGMENTS
TABLE 115. GENINCODE: PRODUCT PORTFOLIO
TABLE 116. GENINCODE: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 117. ATRYS HEALTH: KEY EXECUTIVES
TABLE 118. ATRYS HEALTH: COMPANY SNAPSHOT
TABLE 119. ATRYS HEALTH: OPERATING SEGMENTS
TABLE 120. ATRYS HEALTH: PRODUCT PORTFOLIO
TABLE 121. ATRYS HEALTH: KEY STRATEGIC MOVES AND DEVELOPMENTS
LIST OF FIGURES
FIGURE 1. GLOBAL HUMAN GENETICS MARKET, 2024 - 2033
FIGURE 2. SEGMENTATION OF HUMAN GENETICS MARKET, 2024 - 2033
FIGURE 3. TOP INVESTMENT POCKET IN HUMAN GENETICS MARKET
FIGURE 4. MODERATE BARGAINING POWER OF BUYERS
FIGURE 5. MODERATE BARGAINING POWER OF SUPPLIERS
FIGURE 6. MODERATE THREAT OF NEW ENTRANTS
FIGURE 7. LOW THREAT OF SUBSTITUTION
FIGURE 8. HIGH COMPETITIVE RIVALRY
FIGURE 9. OPPORTUNITIES, RESTRAINTS AND DRIVERS: GLOBALHUMAN GENETICS MARKET
FIGURE 10. GLOBAL HUMAN GENETICS MARKET SEGMENTATION, BY TEST
FIGURE 11. HUMAN GENETICS MARKET FOR NIPT, BY COUNTRY, 2024 - 2033 ($MILLION)
FIGURE 12. HUMAN GENETICS MARKET FOR CARRIER TESTING, BY COUNTRY, 2024 - 2033 ($MILLION)
FIGURE 13. HUMAN GENETICS MARKET FOR PHARMACOGENOMIC TESTING, BY COUNTRY, 2024 - 2033 ($MILLION)
FIGURE 14. HUMAN GENETICS MARKET FOR KARYOTYPE TESTING, BY COUNTRY, 2024 - 2033 ($MILLION)
FIGURE 15. HUMAN GENETICS MARKET FOR THROMBOPHILIA TESTING, BY COUNTRY, 2024 - 2033 ($MILLION)
FIGURE 16. HUMAN GENETICS MARKET FOR SEPTIN 9 BIOMARKER TESTING, BY COUNTRY, 2024 - 2033 ($MILLION)
FIGURE 17. HUMAN GENETICS MARKET FOR NGS, BY COUNTRY, 2024 - 2033 ($MILLION)
FIGURE 18. HUMAN GENETICS MARKET FOR OTHERS, BY COUNTRY, 2024 - 2033 ($MILLION)
FIGURE 19. GLOBAL HUMAN GENETICS MARKET SEGMENTATION, BY APPLICATION
FIGURE 20. HUMAN GENETICS MARKET FOR WELLNESS E-COMMERCE, BY COUNTRY, 2024 - 2033 ($MILLION)
FIGURE 21. HUMAN GENETICS MARKET FOR PREVENTIVE MEDICINE, BY COUNTRY, 2024 - 2033 ($MILLION)
FIGURE 22. HUMAN GENETICS MARKET FOR DIAGNOSTIC TREATMENT, BY COUNTRY, 2024 - 2033 ($MILLION)
FIGURE 23. TOP WINNING STRATEGIES, BY YEAR, 2021-2023*
FIGURE 24. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2021-2023*
FIGURE 25. TOP WINNING STRATEGIES, BY COMPANY, 2021-2023*
FIGURE 26. PRODUCT MAPPING OF TOP 10 PLAYERS
FIGURE 27. COMPETITIVE DASHBOARD
FIGURE 28. COMPETITIVE HEATMAP: HUMAN GENETICS MARKET
FIGURE 29. TOP PLAYER POSITIONING, 2023
FIGURE 30. MYRIAD GENETICS: NET SALES, 2021-2023 ($MILLION)
FIGURE 31. MYRIAD GENETICS: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 32. MYRIAD GENETICS: REVENUE SHARE, BY REGION, 2023 (%)
FIGURE 33. SYNLAB GROUP: NET SALES, 2021-2023 ($MILLION)
FIGURE 34. SYNLAB GROUP: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 35. SYNLAB GROUP: REVENUE SHARE, BY REGION, 2023 (%)
FIGURE 36. EUROFINS MEGALAB S.A.: NET SALES, 2021-2023 ($MILLION)
FIGURE 37. EUROFINS MEGALAB S.A.: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 38. EUROFINS MEGALAB S.A.: REVENUE SHARE, BY REGION, 2023 (%)
FIGURE 39. BIOMARKER TECHNOLOGIES: NET SALES, 2021-2023 ($MILLION)
FIGURE 40. BIOMARKER TECHNOLOGIES: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 41. BIOMARKER TECHNOLOGIES: REVENUE SHARE, BY REGION, 2023 (%)
FIGURE 42. ECHEVARNE LABORATORY: NET SALES, 2021-2023 ($MILLION)
FIGURE 43. ECHEVARNE LABORATORY: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 44. ECHEVARNE LABORATORY: REVENUE SHARE, BY REGION, 2023 (%)
FIGURE 45. ELABSCIENCE BIOTECHNOLOGY INC: NET SALES, 2021-2023 ($MILLION)
FIGURE 46. ELABSCIENCE BIOTECHNOLOGY INC: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 47. ELABSCIENCE BIOTECHNOLOGY INC: REVENUE SHARE, BY REGION, 2023 (%)
FIGURE 48. NIMGENETICS: NET SALES, 2021-2023 ($MILLION)
FIGURE 49. NIMGENETICS: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 50. NIMGENETICS: REVENUE SHARE, BY REGION, 2023 (%)
FIGURE 51. SISTEMAS GENóMICOS: NET SALES, 2021-2023 ($MILLION)
FIGURE 52. SISTEMAS GENóMICOS: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 53. SISTEMAS GENóMICOS: REVENUE SHARE, BY REGION, 2023 (%)
FIGURE 54. FULLGENOMICS: NET SALES, 2021-2023 ($MILLION)
FIGURE 55. FULLGENOMICS: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 56. FULLGENOMICS: REVENUE SHARE, BY REGION, 2023 (%)
FIGURE 57. GENINCODE: NET SALES, 2021-2023 ($MILLION)
FIGURE 58. GENINCODE: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 59. GENINCODE: REVENUE SHARE, BY REGION, 2023 (%)
FIGURE 60. ATRYS HEALTH: NET SALES, 2021-2023 ($MILLION)
FIGURE 61. ATRYS HEALTH: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 62. ATRYS HEALTH: REVENUE SHARE, BY REGION, 2023 (%)

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us